Archives
The non-approval of aducanumab in Europe still marks a significant stride forward in dementia research
17 December 2021
An opinion piece by Professor John O’Brien, NIHR Clinical Research Network National Specialty Lead for Dementias The European Medicines Agency (EMA) has today said no to approving aducanumab – a new drug to treat Alzheimer’s disease. EMA considered that although the drug removed amyloid, a toxic protein that builds up in the brains of people […]
Breakthrough Alzheimer’s drug approved in the US
8 June 2021
The US Food and Drug Administration (FDA) has this week approved the first drug since 2003 to treat Alzheimer’s disease. Aducanumab, created by US pharmaceutical company Biogen, is an antibody designed to target amyloid, a protein that builds up in the brains of people with early stages of Alzheimer’s disease. Whereas other existing treatments help […]